- Ottobre 2024

Schmid P, Cortes J, Dent R, et al.

Overall survival with pembrolizumab in early-stage triple-negative breast cancer

N Engl J Med 2024 Sep 15. Epub ahead of print

Simonpietro Marrocco Ottobre 2024

Leggi abstract | Scarica ppt

---

Bardia A, Hu X, Dent R, et al.

Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer

N Engl J Med 2024 Sep 15. Epub ahead of print

Simonpietro Marrocco Ottobre 2024

Leggi abstract | Scarica ppt

---

De Sanctis R, Tiberio P, Jacobs F, et al.

Optimizing abemaciclib-induced diarrhea management in patients with breast cancer: a pragmatic 2-group study using a postbiotic microbiota stabilizer

Oncologist 2024;29(9):e1113-e1119

Simonpietro Marrocco Ottobre 2024

Leggi abstract | Scarica ppt

---

Qureshi Z, Jamil A, Fatima E, et al.

Efficacy and safety of abemaciclib in combination with endocrine therapy for HR+/HER2- advanced or metastatic breast cancer: a systematic review and meta-analysis

Am J Clin Oncol 2024 Sep 9. Epub ahead of print

Simonpietro Marrocco Ottobre 2024

Leggi abstract | Scarica ppt

---

Dilawari A, Buturla J, Osgood C, et al.

US Food and Drug Administration approval summary: capivasertib with fulvestrant for hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer with PIK3CA/AKT1/PTEN alterations

J Clin Oncol 2024 Aug 19:JCO2400427. Epub ahead of print

Simonpietro Marrocco Ottobre 2024

Leggi abstract | Scarica ppt

---

Oliveira M, Rugo HS, Howell SJ, et al.

Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial

Lancet Oncol 2024;25(9):1231-1244

Simonpietro Marrocco Ottobre 2024

Leggi abstract

---

Zuley ML, Bandos AI, Duffy SW, et al.

Breast cancer screening interval: effect on rate of late-stage disease at diagnosis and overall survival

J Clin Oncol 2024 Aug 21:JCO2400285. Epub ahead of print

Simonpietro Marrocco Ottobre 2024

Leggi abstract

---

Bardia A, Jhaveri K, Im SA, et al.

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01

J Clin Oncol 2024 Sep 12:JCO2400920. Epub ahead of print

Simonpietro Marrocco Ottobre 2024

Leggi abstract

---

Loibl S, Jassem J, Sonnenblick A, et al.

Adjuvant pertuzumab and trastuzumab in early human epidermal growth factor receptor 2-positive breast cancer in the APHINITY trial: third interim overall survival analysis with efficacy update

J Clin Oncol 2024 Sep 11:JCO2302505. Epub ahead of print

Simonpietro Marrocco Ottobre 2024

Leggi abstract

---

Jhaveri KL, Lim E, Jeselsohn R, et al.

Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and in combination with targeted therapy in estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: phase Ia/Ib EMBER Study

J Clin Oncol 2024 Sep 6:JCO2302733. Epub ahead of print

Simonpietro Marrocco Ottobre 2024

Leggi abstract

---

Geurts VCM, Balduzzi S, Steenbruggen TG, et al.

Tumor-infiltrating lymphocytes in patients with stage i triple-negative breast cancer untreated with chemotherapy

JAMA Oncol 2024;10(8):1077-1086

Simonpietro Marrocco Ottobre 2024

Leggi abstract

---

Park KU, Lipsitz S, Dominici LS, et al.

Generative artificial intelligence as a source of breast cancer information for patients: proceed with caution

Cancer 2024 Aug 30. Epub ahead of print

Simonpietro Marrocco Ottobre 2024

Leggi abstract

---

André F, Cortés J, Curigliano G, et al.

A pooled analysis of trastuzumab deruxtecan in patients with her2-positive metastatic breast cancer with brain metastases

Ann Oncol 2024 Sep 4:S0923-7534(24)03928-0. Epub ahead of print

Simonpietro Marrocco Ottobre 2024

Leggi abstract

---

Pagliuca M, Havas J, Thomas E, et al.

Long-term behavioral symptom clusters among survivors of early-stage breast cancer. Development and validation of a predictive model

J Natl Cancer Inst 2024 Sep 9:djae222. Epub ahead of print

Simonpietro Marrocco Ottobre 2024

Leggi abstract

---

André F, Solovieff N, Su F, et al.

Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials

Ann Oncol 2024 Sep 21:S0923-7534(24)04018-3. Epub ahead of print

Simonpietro Marrocco Ottobre 2024

Leggi abstract

---